Bahman Jabbari MD
Professor of Neurology; Director, Division of Parkinson's disease and Movement Disorders; Director, Botulinum Toxin treatment program
Parkinson's disease; Movement disorders (dystonia, tremor, chores, tics , tardive dyskinesias); New indications for botulinum toxin treatment in clinical medicine (variety of pain disorders, spasticity and rigidity, etc); Central and peripheral electrophysiology (EEG/EMG); Deep brain stimulation
see research description
current research is focused to improve a number of movement disorders and pain disorders with the use of botulinum toxins ( subcutaneous or intramuscular treatment )
Approved ongonig protocols ,free of charge to the patients are available for low back pain , restless legs syndrome , tremor of parkinson's disese and essential tremor and local pain related to cancer surgery ( resection , biopsy , radiation ).
Extensive Research Description
Current research is geared to investigate efficacy of botulinum type A toxins in treatment of hyperkinetic movement and pain related to neuological disorders. botulinum toxins are found to have analgesic effect due to inhibition of release of pain modulators (substance P, calcitonin-gene related peptide, etc) . The followin ongoing 4 protocols are available for subjects participation :
1- Investigation of efficacy of Xeomin (type A toxin) in local cancer pain (after surgery, biopsy , radiation)
2- investigation of efficacy of Dysport in low back pain ( double blind, parallel , placebo controlled)
3- Investigation of efficacy of xeomin in Parkinson tremor ( double blind , cross over, placebo controlled)
4- investigation of efficacy of Xeomin in essential tremor (double blind , crossover, placebocontrolled)
Both Xeomin and Dysport are type A toxin (like botox) and approved by FDA for use in US ( cervical dystonia , blepharospasm)
All protocols are approved by Yale HIC committee.
Intereted subjects call : 203- 737-2464 and leave message.
PI's Drs Jabbari and Machado , protocol coordinator Dr.Rostami